Announcements Trials
Browse Landscape

Phase

Phase 2 13Phase 1/2 5Phase 3 3Phase NA 2Phase 4 1Phase 2/3 1

Status

Not yet recruiting 5Recruiting 4Unknown 3Completed 2Active not recruiting 2Terminated 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 5

Conditions

Colorectal Neoplasms 2To Evaluate the Efficacy of Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Colorectal Carcinoma 1Stomach Neoplasms 1Esophageal Squamous Cell Carcinoma 1

Interventions

Bevacizumab 14Injections 13Drug Therapy 10Gemcitabine 9venetoclax 7toripalimab 7pembrolizumab 7Specimen Handling 7Magnetic Resonance Spectroscopy 7Cyclophosphamide 7irinotecan sucrosofate 6Temozolomide 6Fluorouracil 6tislelizumab 5fludarabine 5N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 5HMPL-013 5Etoposide 5Dexamethasone 5Cisplatin 5Carboplatin 5Capecitabine 5Biopsy 5sintilimab 4lenvatinib 4Rituximab 4Radiotherapy 4Pemetrexed 4Paclitaxel 4Oxaliplatin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1/2 × Not yet recruiting × HMPL-013 × Clear all
NCT07591597 2026-05-18

IGNITE-CRC

National Cancer Center Hospital East

Phase 1/2 Not yet recruiting
68 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT06871527 2025-03-12

Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer

Sixth Affiliated Hospital, Sun Yat-sen University

Phase 1/2 Not yet recruiting
44 enrolled
Gastrointestinal

Stomach Neoplasms

NCT06484153 2024-07-03

Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 1/2 Not yet recruiting
25 enrolled
Gastrointestinal

To Evaluate the Efficacy of Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Colorectal Carcinoma

NCT06195670 2024-01-08

Clinical Study of Short-course Radiotherapy Followed by Fruquintinib Plus Sintilimab vs Bevacizumab Plus Capecitabine as First Line Treatment in Advanced mCRC

Zhejiang Cancer Hospital

Phase 1/2 Not yet recruiting
220 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT06010212 2023-08-24

Fruquintinib as First Line Treatment in Patients With Recurrent Esophageal Squamous Cell Carcinoma

The First Affiliated Hospital with Nanjing Medical University

Phase 1/2 Not yet recruiting
36 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡